Press Releases

Press Releases

Date Title  
May 13, 2021 Omeros’ Narsoplimab Pivotal Trial Data to Be Shared as an Oral Presentation at the European Hematology Association Congress
SEATTLE --(BUSINESS WIRE)--May 13, 2021-- Omeros Corporation (Nasdaq: OMER) today announced that data on organ function improvement from Omeros’ pivotal trial of narsoplimab for the treatment of hematopoietic stem cell transplant-associated thrombotic microangiopathy (HSCT-TMA) will be shared as an
May 10, 2021 Omeros Corporation Reports First Quarter 2021 Financial Results
– Conference Call Today at 4:30 p.m. ET – SEATTLE --(BUSINESS WIRE)--May 10, 2021-- Omeros Corporation (Nasdaq: OMER), a commercial-stage biopharmaceutical company committed to discovering, developing and commercializing small-molecule and protein therapeutics for large-market as well as orphan
May 05, 2021 Omeros Corporation to Announce First Quarter Financial Results on May 10, 2021
SEATTLE --(BUSINESS WIRE)--May 5, 2021-- Omeros Corporation (NASDAQ: OMER), today announced that the company will issue its first quarter financial results for the period ended March 31, 2021 , on Monday, May 10, 2021 , after the market closes. Omeros management will host a conference call and
May 04, 2021 Omeros Corporation Announces Approval of ICD-10 Codes for HSCT-TMA Diagnosis and for Narsoplimab Administration
SEATTLE --(BUSINESS WIRE)--May 4, 2021-- Omeros Corporation (Nasdaq: OMER) today announced that the Centers for Disease Control and Prevention ( CDC ) has approved an International Classification of Diseases (ICD-10) diagnosis code, M31.11 – hematopoietic stem cell transplantation-associated
Mar 23, 2021 Omeros and Quantum Leap Announce First Patients Dosed with Narsoplimab in the I-SPY COVID-19 Trial
-- Adaptive Platform Trial is Evaluating Drugs and Investigational Products in the Treatment of Critically Ill COVID-19 Patients -- SEATTLE & SAN FRANCISCO --(BUSINESS WIRE)--Mar. 23, 2021-- Omeros Corporation (Nasdaq: OMER) and Quantum Leap Healthcare Collaborative announced that dosing of
Mar 01, 2021 Omeros Corporation Reports Fourth Quarter and Year-End 2020 Financial Results
– Conference Call Today at 4:30 p.m. ET – SEATTLE --(BUSINESS WIRE)--Mar. 1, 2021-- Omeros Corporation (Nasdaq: OMER), a commercial-stage biopharmaceutical company committed to discovering, developing and commercializing small-molecule and protein therapeutics for large-market as well as orphan
Feb 25, 2021 Omeros Corporation to Announce Fourth Quarter and Year-End Financial Results on March 1, 2021
SEATTLE --(BUSINESS WIRE)--Feb. 25, 2021-- Omeros Corporation (NASDAQ: OMER), today announced that the company will issue its fourth quarter and year-end financial results for the period ended December 31, 2020 , on Monday, March 1, 2021 , after the market closes.
Jan 26, 2021 Omeros Hires Nadia Dac as Chief Commercial Officer
SEATTLE --(BUSINESS WIRE)--Jan. 26, 2021-- Omeros Corporation (Nasdaq: OMER) today announced that Nadia Dac has joined Omeros as its Chief Commercial Officer. In this role, Ms. Dac will be responsible for all commercial operations at Omeros, including overseeing preparations for the commercial
Jan 19, 2021 Biologics License Application for Narsoplimab in HSCT-TMA Accepted for Priority Review by U.S. FDA
-- FDA sets PDUFA date of July 17, 2021 -- SEATTLE --(BUSINESS WIRE)--Jan. 19, 2021-- Omeros Corporation (Nasdaq: OMER) announced today that the Biologics License Application (BLA) for narsoplimab for the treatment of hematopoietic stem cell transplant-associated thrombotic microangiopathy
Jan 11, 2021 Omeros to Present at the 39th Annual J.P. Morgan Healthcare Conference
SEATTLE --(BUSINESS WIRE)--Jan. 11, 2021-- Omeros Corporation (Nasdaq: OMER) today announced that Gregory A. Demopulos , M.D., chairman and chief executive officer, will present at the 39 th Annual J.P. Morgan Healthcare Conference this week. This conference is being held as a virtual conference